Prevalence of BRAF V600E Mutation in the Iranian Patients with Hairy Cell Leukemia: A Retrospective Study

Mojatba Karimi¹, Ahmad Monabbati², Nasibe Sargazi Moghaddam³

¹Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran. ²Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran. ³Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

Objective: BRAF V600E mutation has several implications in hairy cell leukemia (HCL). The prevalence of this mutation has been investigated in various populations, but not in Iran. In this study, we evaluated the prevalence of BRAF V600E mutation in an Iranian HCL population as well as its association with the patients’ characteristics.

Methods: In a retrospective (archival) study, 20 HCL patients with the confirmed immunophenotypic and morphologic diagnosis were included. Paraffin-embedded blocks of bone marrow aspirate were used to investigated BRAF V600E mutation using amplification refractory mutation system (ARMS) PCR. Demographic, clinical, laboratory, and immunophenotypic characteristics of patients were extracted from the patients medical profiles.

Result: BRAF V600E mutation was present in 17 (85%) HCL patients and absent in three (15%) patients. The mean age of the patients was 44.76 ± 8.69 years in mutation-positive and 62.33 ± 8.69 in mutation-negative patients. This difference was statistically significant (p=0.013). No significant difference was found between the laboratory indices of the mutation-positive and mutation-negative groups. The clinical, morphologic, and immunophenotypic characteristics of the two groups were also statistically comparable.

Conclusion: BRAF V600E mutation is present in the majority of the Iranian HCL patients and is associated with younger age of presentation.

Keywords: BRAF V600E- Hairy Cell Leukemia- Mutation
in over 97% of the HCL cases so far investigated [7], a lower frequency of BRAF mutations (79%) has also been reported [8]. Considering the implications of BRAF V600E mutation for the pathogenesis, diagnosis, prognosis, and targeted therapy of HCL, evaluation of its prevalence in different HCL populations is of critical importance [4]. However, the prevalence of BRAF V600E mutation in the Iranian HCL population has not been studied in earlier investigations. In this multi-center study, we evaluate the prevalence of BRAF V600E mutation in Iranian HCL patients.

Materials and Methods

Study design and data collection

This retrospective (archival) study was approved by the review board of our institute. The target population was consecutive HCL patients who were referred to the oncology hospitals of Shiraz, Iran, between 2012 and 2015. Patients with a confirmed immunophenotypic and morphologic diagnosis of HCL were included, providing that their paraffin-embedded block of bone marrow aspirate was available for genetic evaluation. Finally, 20 patients were identified as eligible for the study. Demographic, clinical, laboratory, and immunophenotypic characteristics of patients were extracted from the patients medical profiles.

Evaluation of BRAF V600E mutation

After deparaffinization of paraffin-embedded sections, DNA was extracted using GeNet Bio kit (GeNet Bio inc. Daejeon, South Korea). The quality and quantity of DNA were assessed with a nanodrop-1000 spectrophotometer. Then DNA amplification was done using amplification refractory mutation system-polymerase chain (ARMS-PCR) as earlier described [9]. The ARMS-PCR primer sequences are demonstrated in Table 1. Four PCR primers were included in one PCR tube. Accordingly, F-R primer pair amplifies a common 200 bp fragment flanking the site of mutation. F-Rmi primer pair amplifies a fragment of 144 bp specific to the BRAF V600E mutation. Fwi-R primer pair amplifies a 97 bp fragment specific to wild-type BRAF gene.

PCR was performed in a 25 μl final volume, which included 1 × Buffer, 30 ng extracted DNA template, 2 mM MgCl2, 1 unit of Hotstar Taq DNA polymerase (Qiagen Science, Valencia, CA), 200 μM of dNTPs, 400 nM primer F, 200 nM primer R, 200 nM primed Fwi, and 800 nM primer Rmi. PCR was started with denaturation at 95°C for 5 min, followed by 40 cycles of 94°C for 20 sec, 62°C for 20 sec and 72°C for 20 sec, and a final extension step at 72°C for 5 min. PCR products were analyzed by 2.5% agarose gel electrophoresis and were visualized under UV light (Figure 1).

Statistical analysis

SPSS for Windows version 16 (SPSS Inc., Chicago, Ill., USA) was used for the statistical analysis of the data. Descriptive statistics were demonstrated with mean ± standard deviation or number & percentage. A Mann–Whitney U test was used to compare quantitative variables across two groups. A chi-square test was used to evaluate the statistical association between categorical variables. A p-value of fewer than 0.05 was considered statistically significant.

Results

The study population included 19 (95%) males and one (5%) female with a mean age of 47.4±10.3 years (range 28-66). BRAF V600E mutation was positive in 17 (85%) patients and negative in three (15%) patients. The mean age of the patients was significantly lower in patients with positive BRAF V600E mutation (p=0.013). No other significant association was found between the patients with and without BRAF V600E mutation. Laboratory indices were also statistically comparable between the two groups (Table 2).

The mean size of the spleen was 18.7±2.3 cm in the negative and 17.4±3.5 cm in the positive BRAF V600E mutation group (p=0.416). Accordingly, splenomegaly was noticed in one patient of the positive BRAF V600E group and no patient of the negative BRAF V600E group (p=0.666). No other significance was also found between the clinical features of the two groups. Bone marrow morphology was statistically comparable between the two groups, as well (Table 3). Moreover, no significant difference was found between the immunophenotypic characteristics of the two groups (Table 4).

Table 1. The ARMS-PCR primer sequences for the detection of BRAF V600E

| Forward (F)                      | 5’–CTC TTC ATA ATG CTG GTCT GTGA ATA G-3’ |
|----------------------------------|------------------------------------------|
| Reverse (R)                      | 5’-GCCTCAATTCTTACCATCCAC-3’              |
| Forward wild-type identifying (Fwi)| 5’-GTGATTGTGGTCT AGCTACAGT-3’           |
| Reverse mutation identifying: (Rmi)| 5’-CCCACCTCCATCGAGTTTCT-3’              |

Figure 1. Evaluation of PCR Products on the Agarose Gel Electrophoresis under UV Light
BRAF V600E mutation was detected in 36 out of 51 patients (70.5%) [12]. Bibi et al. detected BRAF V600E mutation in 89.1% (41/46 patients) of the Indian HCL population [11]. In the present study, we detected BRAF V600E mutation in 85% of Iranian HCL patients that was similar to that reported in the study of Bibi et al [11]. Nonetheless, the difference between studies could be attributed to the method of detection. Blombery et al. used high resolution melting analysis and confirmatory Sanger sequencing for the detection of BRAF V600E mutation. The detected mutations were not equal using the two methods, so that high resolution melting analysis detected mutation in 42 samples, which was confirmed by sequencing in 38 [12]. Therefore, the method of evaluation could be regarded as a source of heterogeneity between the studies.

Langabeer et al. evaluated the correlation of the BRAF V600E mutation with immunophenotypic characteristics of the 24 patients with a classic HCL. The CD11c+/CD20+/CD25+/FMC7+ HCL immunophenotype was detected in 23 HCL patients. BRAF V600E mutation was also detected in 23 patients. They suggested a high degree of correlation between the presence of BRAF

**Table 2. Comparison of Demographic and Laboratory Characteristics between BRAF V600E Positive and Negative Patients**

| Variables          | BRAF Gene Mutation |
|--------------------|--------------------|
|                    | Negative (n=3)     | Positive (n=17) | P-value |
| Sex                |                    |                |
| · Male             | 3 (100)            | 16 (94.1)      | 0.666   |
| · Female           | 0                  | 1 (5.9)        |         |
| Age (years)        | 62.33 ± 8.69       | 44.76 ± 8.69   | 0.013*  |
| WBC count (/µL)    | 2733 ± 2020        | 2241 ± 868     | 0.468   |
| Neutrophil (%)     | 50 ± 18            | 39 ± 18        | 0.356   |
| Lymphocyte (%)     | 50 ± 18            | 60 ± 18        | 0.364   |
| Hemoglobin (g/dL)  | 9.8 ± 4.2          | 9.9 ± 1.7      | 0.91    |
| Platelet count (/µL)| 81000 ± 32908     | 55411 ± 26260  | 0.149   |

Data are presented as mean ± SD or number (%). P <0.05 is considered significant.

**Table 3. Comparison of Clinical and Morphologic Features between BRAF V600E Positive and Negative Patients**

| Variables              | BRAF gene mutation |
|------------------------|--------------------|
|                       | Negative (n=3)     | Positive (n=17) | P-value |
| Hospital Admissions    |                    |                |
| · Once                 | 0                  | 2 (11.8)       | 0.555   |
| · Twice & More         | 3 (100)            | 12 (70.6)      |         |
| · Never                | 0                  | 3 (17.6)       |         |
| Spleen size (cm)       | 18.7±2.3 †         | 17.4±3.5 †     | 0.416   |
| Splenomegaly           |                    |                |
| · Yes                  | 0                  | 1 (5.9)        | 0.666   |
| · No                   | 3 (100)            | 16 (94.1)      |         |
| Bone marrow Morphology |                    |                |
| · Hypocellular         | 2 (66.7)           | 5 (29.4)       |         |
| · Hypercellular        | 0                  | 3 (17.6)       | 0.42    |
| · Mosaic-pattern       | 1 (33.3)           | 9 (53)         |         |

Data are presented as mean ± SD or number (%). P <0.05 is considered significant.

**Discussion**

In this study, we evaluated the presence of BRAF V600E mutation in Iranian HCL patients in a metacentric study. We also investigated the association of this mutation with the patients’ characteristics. According to this study, BRAF V600E mutation was present in 85% of HCL patients. Patients with negative BRAF V600E mutation had significantly higher age. No significant association was found between the BRAF V600E mutation and characteristics of HCL patients such as laboratory indices, immunophenotypic markers, etc.

In earlier studies, various rates have been reported for BRAF V600E mutation in HCL patients. Tiacci et al. evaluated the BRAF V600E mutation in 47 Italian HCL patients. BRAF V600E mutation was present in all patients [4]. Boyd et al. reported 100% BRAF V600E mutation (n=48) in English HCL patients [10]. Arciani et al. assessed BRAF V600E mutation in 62 HCL patients. BRAF V600E mutation was detected in all cases [11]. Blombery et al. investigated BRAF V600E mutation in 51 Australian HCL patients (59 samples). In total, BRAF V600E mutation was detected in 36 out of 51 patients (70.5%) [12]. Bibi et al. detected BRAF V600E mutation in 89.1% (41/46 patients) of the Indian HCL population [11]. In the present study, we detected BRAF V600E mutation in 85% of Iranian HCL patients that was similar to that reported in the study of Bibi et al [11]. Nonetheless, the difference between studies could be attributed to the method of detection. Blombery et al. used high resolution melting analysis and confirmatory Sanger sequencing for the detection of BRAF V600E mutation. The detected mutations were not equal using the two methods, so that high resolution melting analysis detected mutation in 42 samples, which was confirmed by sequencing in 38 [12]. Therefore, the method of evaluation could be regarded as a source of heterogeneity between the studies.

Langabeer et al. evaluated the correlation of the BRAF V600E mutation with immunophenotypic characteristics of the 24 patients with a classic HCL. The CD11c+/CD20+/CD25+/FMC7+ HCL immunophenotype was detected in 23 HCL patients. BRAF V600E mutation was also detected in 23 patients. They suggested a high degree of correlation between the presence of BRAF
V600E mutation and established diagnostic criteria and highlighted the value of a multifaceted approach to the diagnosis of HCL [13]. We could not detect the association between BRAF V600E mutation and immunophenotypic characteristics due to the high missing data in this section.

In the study of Bibi et al. HCL patients with BRAF V600E mutation presented at a younger age. However, no significant difference was found between the other characteristic features of the patients with and without BRAF mutation, such as in laboratory parameters [14]. We also detected an association between BRAF V600E mutation and the age of the presentation, so that patients with BRAF V600E mutation were significantly younger. Similar to the study of Bibi et al. laboratory indices were not associated with BRAF V600E mutation in the present study.

The present study has several weaknesses. First, the PCR results were not confirmed by sequencing. Second, the number of patients in the negative BRAF mutation group was considerably small. Therefore, the power of statistical analysis could be poor. Finally, a significant number of data were missing, particularly in immunophenotypic characteristics. Therefore, future studies with larger patients’ numbers are required to confirm the results of this study.

In conclusion, BRAF V600E mutation was present in 85% of Iranian HCL patients and absent in 15%. The presence of the mutation was associated with the younger age of the patients, but not with other patients’ characteristics such as immunophenotypic and laboratory indices. Our finding suggests a diagnostic role for BRAF V600E mutation in the Iranian HCL population.

**Acknowledgements**

We would like to thank the Shiraz University of Medical Sciences for providing the infrastructure and implications for this study, and we would especially like to thank Mrs. Valibegi, a medical school technician, for all her efforts and support during this study.

---

**Table 4. Distribution of Immunophenotypic Markers According to BRAF Gene Mutation (when the sum of subsets is not equal to the total patients’ number, there is missing data)**

| Variables | BRAF gene mutation | P-value |
|-----------|--------------------|---------|
|           | Negative (n=3)     | Positive (n=17) |       |
| CD3       | 1 (33.3)           | 2 (18.2)   | 0.571  |
|           | 2 (66.7)           | 9 (81.8)   |         |
| CD5       | 0                  | 2 (16.7)   | 0.666  |
|           | 2 (100)            | 12 (83.3)  |         |
| CD7       | 0                  | 2 (100)    | 0.083  |
|           | 1 (100)            | 0          |         |
| CD8       | 1 (100)            | 2 (66.7)   | 0.505  |
|           | 0                  | 1 (33.3)   |         |
| CD10      | 0                  | 2 (20)     | 0.621  |
|           | 1 (100)            | 8 (80)     |         |
| CD11c     | 2 (100)            | 16 (94.1)  | 0.725  |
|           | 0                  | 1 (5.9)    |         |
| CD19      | 2 (100)            | 7 (87.5)   | 0.598  |
|           | 0                  | 1 (12.5)   |         |
| CD20      | 1 (33.3)           | 11 (64.7)  | 0.306  |
|           | 2 (66.7)           | 6 (35.3)   |         |
| FMC7      | 0                  | 1 (100)    | 0.157  |
|           | 1 (100)            | 0          |         |

Data are presented as number (%). P <0.05 is considered significant.
Funding Statement
This thesis is supported by deputy dean of School of Medicine based on research project number 7008 dated 1392/1/1 and sponsored by deputy chancellor of Shiraz University of Medical Sciences.

Statement conflict of Interest
No potential conflict of interest was reported by the authors.

References
1. Troussard X, Cornet E. Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment. American Journal of Hematology. 2017 Nov 07;92(12):1382-1390. https://doi.org/10.1002/ajh.24936

2. Durham BH, Getta B, Dietrich S, Taylor J, Won H, Bogenberger JM, Scott S, Kim E, Chung YR, Chung SS, Hülein J, Walther T, Wang L, Lu SX, Oakes CC, Tíbes R, Haferlach T, Taylor BS, Tallman MS, Berger MF, Park JH, Zenz T, Abdel-Wahab O. Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood. 2017 Oct 05;130(14):1644-1648. https://doi.org/10.1182/blood-2017-01-765107

3. Ahmadzadeh A, Shahrahi S, Jaseb K, Noroozi F, Shahjahani M, Vosoughi T, Hajizamani S, Saki N. BRAF mutation in hairy cell leukemia. Oncology Reviews. 2014 09 23; https://doi.org/10.4081/oncol.2014.253

4. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Boveri E, Riboni R, Rattotti S, Varettoni M, Guerrera ML, Lucioni M, Tenore A, Merli M, Rizzi S, Morello L, Cavalloni C, Da Vià MC, Paulli M, Cazzola M. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012 01 05;119(1):188-191. https://doi.org/10.1182/blood-2011-08-368209

12. Blombery PA, Wong SQ, Hewitt CA, Dobrovic A, Maxwell EL, Juneja S, Grigoriadis G, Westerman DA. Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica. 2011 Dec 01;97(5):780-783. https://doi.org/10.3324/haematol.2011.054874

13. Langabeer SE, O’brien D, Liptrot S, Flynn CM, Hayden PJ, Connelly E, Browne PW, Vandenberghe E. Correlation of the Braf600e mutation in hairy cell leukemia with morphology, cytochemistry and immunophenotype. International Journal of Laboratory Hematology. 2012 02 07;34(4):417-421. https://doi.org/10.1111/j.1751-553x.2012.01402.x

14. Patkar N, Bibi A, Java S, Chaudhary S, Joshi S, Mascherenas R, Rabade N, Tembhare P, Subramanian P, Gujral S, Menon H, Khattry N, Sengar M, Bagal B, Jain H. Braf600e mutation in hairy cell leukemia: A single-center experience. Indian Journal of Pathology and Microbiology. 2018;61(4):532. https://doi.org/10.4103/ijpm.ijpm_484_16

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.